Androgel Osteopenia Osteoporosis

Androgel osteopenia osteoporosis treatment. Low testosterone is a major cause of osteopenia and osteoporosis in men. Androgel is a topical testosterone pharmeceutical medication. It contains 1 per cent
testoesterone and is prescribed to men with hypogonadism or low testosterone production.

The drug is clear and colorless and it is used topicially. This can lead to some problems which are outlined later on this page.

Scientific evidence for Androgel osteopenia osteoporosis treatment.

In 2010 the Journal of American Gerictric Society published an article, Effects of Transdermal Testosterone on Bone and Muscle in Older Men with Low Bioavailable Testosterone Levels, Low Bone Mass and Physical Frailty by Anne M. Kenny, MD, Alison Kleppinger, Kristen Annis, Margaret Rathier, Bruce browner James O. Judge and Daniel McGee

The articles concluded: "Older, frail men receiving testosterone replacement increased testosterone levels, had favorable changes in body composition, modest changes in axial BMD, and no substantial changes physical function." (The significant part of that conclusion for those concerned about Osteopenia and Osteoporosis are the "changes in axial bone mineral density".)

If you want to read the full article, just click on Androgel Osteopenia Osteporosis drug study

Safety of Androgel Osteopenia Osteoporosis treatment.

The Journal of Clinical Intervention Aging published an article, "Safety and efficacy of testosterone gel in the treatment of male hypogonadism" in November 2009. The abstract of the paper states, in part: " Superior tolerability and dose flexibility make testosterone gel highly desirable over other modalities of testosterone replacement." That is encouraging news.

Reference: Journal Inerv. Aging 2009 4. 397-412.

Other effects of Androgel osteopenia osteoporosis treatment.

Farid Saad,Antonio Aversa, Andrea M Isidori, Livia Zafalon, Michael Zitzmann, and Louis Gooren authored "Onset of effects of testosterone treatment and time span until maximum effects are achieved", an article published in Novemeber of 2011. This article reviewed many
studies about testosterone treatments. Their article states:

"Effects on sexual interest appear after 3 weeks plateauing at 6 weeks, with no further increments expected beyond. Changes in erections/ejaculations may require up to 6 months. Effects on quality of life manifest within 3–4 weeks, but maximum benefits take longer.
Effects on depressive mood become detectable after 3–6 weeks with a maximum after 18–30 weeks. Effects on erythropoiesis are evident at 3 months, peaking at 9–12 months. Prostate-specific antigen and volume rise, marginally, plateauing at 12 months; further increase should be related to aging rather than therapy. Effects on lipids appear after
4 weeks, maximal after 6–12 months. Insulin sensitivity may improve within few days, but effects on glycemic control become evident only after 3–12 months. Changes in fat mass, lean body mass, and muscle strength occur within 12–16 weeks, stabilize at 6–12 months, but
can marginally continue over years. Effects on inflammation occur within 3–12 weeks. Effects on bone are detectable already after 6 months while continuing at least for 3 years. (Italics added)

If you are a man with low bone density, you may want to ask your health care provider to test your testoesterone levels. And if they are low you might want to ask about Adrongel.